Printer Friendly

Centella Retires as Nephros Chairman.

M2 PHARMA-December 31, 2015-Centella Retires as Nephros Chairman


- US-based medical device company Nephros, Inc.'s (OTCQB: NEPH) chairman, Lawrence Centella, has decided to retire from the company's board of directors, effective 31 December 2015, the company said on Thursday.

Centella has been the chairman of the board since April 2015, and a member of the board of directors since January 2001.

He has a list of accomplishments in the renal-care industry, most recently serving, from 1998 to 2015, as president of Renal Patient Services, LLC, a company that owned and operated dialysis centers.

Previously, Centella served as executive vice president and chief operating officer of Gambro Healthcare, Inc., as president and chief executive officer of Gambro Healthcare Patient Services, Inc. (formerly REN Corp.), and as president of Gambro/COBE Renal Care, Inc., Gambro Hospal, Inc., LADA International, Inc. and Gambro, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with end stage kidney disease. Its filters, which it calls ultrafilters, are used primarily in medical applications.

The company's ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 31, 2015
Previous Article:Lixte Biotechnology Holdings grants exclusive licence of anti-cancer compound LB-100 to Taipei Medical University.
Next Article:Medical Nonwoven Disposables Market to Reach USD 10.05bn by 2020.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters